FDA re­jects Re­gen­eron’s mul­ti­ple myelo­ma bis­pe­cif­ic an­ti­body over man­u­fac­tur­ing is­sues

The FDA re­ject­ed lin­voseltam­ab, Re­gen­eron’s ex­per­i­men­tal an­ti­body for mul­ti­ple myelo­ma, the com­pa­ny an­nounced Wednes­day morn­ing.

In an earn­ings call ear­li­er this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER